Stocktoria

bioAffinity Technologies, Inc. BIAF

Nasdaq · stock · Services-Commercial Physical & Biological Research · website · IPO 2022-08-26

bioAffinity Technologies, Inc. statistics & valuation

Market cap$5.2M
P / S0.8×
P / B0.7×
Net margin-242.0%
FCF margin-152.4%
Return on capital-131.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-118.20% -100.50% -96.60% -242.00% 20212022202320242025
Gross margin (%)
0.10% 20212022202320242025
Operating margin (%)
-58.10% -100.90% -95.60% -171.60% 20212022202320242025
Return on equity (%)
-73.80% -163.50% -347.40% -204.90% 20212022202320242025
Shares outstanding
2.7M 8.4M 9.4M 519158 4.5M 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-435.30% -66.90% -96.50% -138.80% -136.00% 20212022202320242025
Free cash flow margin (%)
-62.20% -76.70% -78.40% -152.40% 20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$1.81 -$0.91 -$22.50 -$8.66 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Gross margin———0.1%—
Operating margin-171.6%-95.6%-100.9%-58.1%—
Net margin-242.0%-96.6%-100.5%-118.2%—
FCF margin-152.4%-78.4%-76.7%-62.2%—
Return on assets-136.0%-138.8%-96.5%-66.9%-435.3%
Return on equity-204.9%-347.4%-163.5%-73.8%40.1%
Current ratio2.600.871.7710.500.11

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.